NASDAQ:OCRX
Delisted
Ocera Therapeutics Fund Company Profile
$1.79
+0 (+0%)
At Close: Jan 16, 2018
Information
525 University Avenue
Palo Alto CA 94301
650-475-0158
-
Description
Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.
